Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
DexCom (DXCM) PT Lowered to $553 at Cowen
February 11, 2022 7:26 AM ESTCowen analyst Joshua Jennings lowered the price target on DexCom (NASDAQ: DXCM) to $553.00 (from $655.00) while maintaining an Outperform rating.
The analyst commented, "After releasing its 4Q21 sales results and 2022 revenue guidance last month, DXCM today reported its full 4Q21 results and provided its 2022... More
DexCom (DXCM) Misses Q4 EPS by 17c
February 10, 2022 4:05 PM ESTDexCom (NASDAQ: DXCM) reported Q4 EPS of $0.68, $0.17 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $698.2 million versus the consensus estimate of $696.47 million.
GUIDANCE:
DexCom sees FY2022 revenue of $2.82-2.94 billion, versus the consensus of $2.96... More
